CTNND2

Across TCGA pan-cancer cohorts, CTNND2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CTNND2 data layer compared with 21 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTNND2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CTNND2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where CTNND2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.595	0.308	.030	2	view →
GBM	DFS	Quartile	All	0.260	0.576	.018	2	view →
LUAD	DFS	Quartile	All	1.000	0.424	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CTNND2–PDAC (DFS)

Open the PDAC breakdown →